DURLOBACTAM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C8H11N3O6S
Molecular Weight	277.254
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C[C@@H]2C[N@]([C@@H]1C(N)=O)C(=O)N2OS(O)(=O)=O

InChI

InChIKey=BISPBXFUKNXOQY-RITPCOANSA-N

InChI=1S/C8H11N3O6S/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16)/t5-,6+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C8H11N3O6S
Molecular Weight	277.254
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://pubmed.ncbi.nlm.nih.gov/34349751|https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf

Durlobactam is a new member of the diazabicyclooctane class of beta-lactamase inhibitors with broad-spectrum activity against Ambler class A, C, and D serine beta-lactamases. Sulbactam is a first-generation beta-lactamase inhibitor with activity limited to a subset of class A enzymes that also has direct-acting antibacterial activity against Acinetobacter spp. The latter feature is due to sulbactam's ability to inhibit certain penicillin-binding proteins, essential enzymes involved in bacterial cell wall synthesis in this pathogen. Because sulbactam is also susceptible to cleavage by numerous beta-lactamases, its clinical utility for the treatment of contemporary Acinetobacter infections is quite limited. However, when combined with durlobactam, the activity of sulbactam is effectively restored against these notoriously multidrug-resistant strains. In May 2023, the FDA approved Innoviva’s antibiotic, sulbactam-durlobactam (Xacduro), for treatment in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of ABC.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-lactamase 18 Target ID: CHEMBL1075159 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf\|https://pubmed.ncbi.nlm.nih.gov/28665414\|https://pubmed.ncbi.nlm.nih.gov/30288219	Inhibitor 8504		190.0 nM [IC50]
beta-lactamase activity 4 Target ID: GO:0008800 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf\|https://pubmed.ncbi.nlm.nih.gov/28665414	Inhibitor 8504		4.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hospital-acquired bacterial pneumonia 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	Curative		Approved 8583	XACDURO Approved Use XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Launch Date 2023
Ventilator-associated bacterial pneumonia 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	Curative		Approved 8583	XACDURO Approved Use XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Launch Date 2023

C_max

Value	Dose	Co-administered	Analyte	Population
29.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	1 g 4 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
25.5 μg/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
38.7 μg/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
33.3 μg/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
27 μg/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28.6 μg/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21.9 μg/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
39.9 μg/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.01506-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
471 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	1 g 4 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
659 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	1 g 4 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
895 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	1 g 4 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1743 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	1 g 4 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
202 μg × h/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
209 μg × h/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
151 μg × h/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
110 μg × h/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
280 μg × h/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
123 μg × h/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
123.8 μg × h/mL CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.01506-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.51 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	1 g 4 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.4 h CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.8 h CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3 h CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.29 h CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.1 h CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.1 h CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.00794-19	500 mg 4 times / day steady-state, intravenous dose: 500 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.2 h CLINICAL TRIAL https://journals.asm.org/doi/full/10.1128/aac.01506-19	1000 mg 4 times / day steady-state, intravenous dose: 1000 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
90% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf	1 g 4 times / day steady-state, intravenous dose: 1 g route of administration: Intravenous experiment type: STEADY-STATE co-administered: SULBACTAM	SULBACTAM	DURLOBACTAM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 Nav1.5 116 CYP2B6 926 CAV1.2 2 CYP2C8 1057 BCRP 910 OATP1B1 1079 OAT1 725 CYP2E1 1060 OAT3 747 OCT2 779 CYP1A2 2153 CYP2C19 2057 CYP3A5 136 CYP2A6 879	OAT1 395 CYP 303	CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity
CAV1.2 2	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 91.0	no [IC50 >1000 uM]
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 85	no
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 128	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 127	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 127	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 128	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 127	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 128	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 128	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 127	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 84 \| 127 \| 128	no
CYP3A5 201	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 127 \| 128	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 85	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 85	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 85	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 85	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 34 \| 85 \| 129	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 84 \| 85	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 33.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Nav1.5 119	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 91.0
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000IntegratedR.pdf Page: 91.0

PubMed

Title	Date	PubMed
Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex.	2023-08	37442147
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.	2023-05-01	37125470
Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review.	2022-12-10	36551450
Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review.	2022-06-07	35743328
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam.	2021	34349751

Patents

Sample Use Guides

In Vivo Use Guide

Administer XACDURO (1 g of sulbactam, 1 g of durlobactam) every 6 hours by intravenous (IV) infusion over 3 hours in patients with creatinine clearance (CLcr) of 45 to 129 mL/min. (2.1) • Dosing regimen adjustments are recommended for CLcr less than 45 mL/min and CLcr greater than or equal to 130 mL/min. (2.2) • Administer all doses of XACDURO by IV infusion over 3 hours. (2.3)

Route of Administration: Intravenous

In Vitro Use Guide

Durlobactam sodium salt is an inhibitor of beta-lactamase with IC50 values of 4 nM, 14 nM, and 190 nM for Class A KPC-2, Class C AmpC, and Class D OXA-24, respectively.

Substance Class	Chemical Created by `admin` on `Tue Apr 01 21:23:18 GMT 2025` Edited by `admin` on `Tue Apr 01 21:23:18 GMT 2025`
Record UNII	PSA33KO9WA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DURLOBACTAM

Official Name

English

ETX-2514

Preferred Name

English

(2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE

Common Name

English

SULFURIC ACID, MONO((2S,5R)-2-(AMINOCARBONYL)-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL) ESTER

Systematic Name

English

durlobactam [INN]

Common Name

English

ETX2514

Code

English

DURLOBACTAM [USAN]

Common Name

English

Durlobactam [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

89851852